CAS 1204390-13-5
:Immunoglobulin G2, anti-(human insulin-like growth factor I/insulin-like growth factor II) (human monoclonal MEDI-573 heavy chain) disulfide with human monoclonal MEDI-573 λ-chain, dimer
Description:
Immunoglobulin G2 (IgG2), specifically the anti-(human insulin-like growth factor I/insulin-like growth factor II) monoclonal antibody MEDI-573, is a humanized therapeutic antibody designed to target and neutralize the insulin-like growth factors (IGF-I and IGF-II). This antibody is characterized by its dimeric structure, formed by the disulfide linkage between the heavy chain and the lambda (λ) light chain, which is typical for IgG antibodies. IgG2 is known for its unique properties, including a lower ability to activate complement compared to other IgG subclasses, making it suitable for therapeutic applications where minimal immune activation is desired. The specificity of MEDI-573 allows it to inhibit the biological activities of IGF-I and IGF-II, which are involved in various physiological processes and pathologies, including cancer and metabolic disorders. The development of such monoclonal antibodies represents a significant advancement in targeted therapies, providing potential benefits in treating conditions associated with dysregulated IGF signaling.
Formula:Unspecified
Synonyms:- MEDI 573
- Immunoglobulin G2, anti-(human insulin-like growth factor I/insulin-like growth factor II) (human monoclonal MEDI-573 heavy chain) disulfide with human monoclonal MEDI-573 λ-chain, dimer
- Dusigitumab
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 2 products.
Dusigitumab
CAS:A recombinant human monoclonal antibody to circulating insulin-like growth factor (IGF)-I and IGF-2.Dusigitumab
CAS:Dusigitumab (MEDI573) is a fully humanised monoclonal antibody targeting IGF1/IGF2, inhibiting IGF1/IGF2-induced IGF-1R phosphorylation.
Purity:95% - 95%Color and Shape:Liquid
